Fabrication of Gastro-Floating Sustained-Release Etoricoxib and Famotidine Tablets: Design, Optimization , In-Vitro , and In-Vivo Evaluation

• Published in: Pharmaceutical development and technology 2024-05, Vol.29 (5), p.1-444
• Main Authors: Saady, Marwa, Shoman, Nabil A, Teaima, Mahmoud, Abdelmonem, Rehab, El-Nabarawi, Mohamed A, Elhabal, Sammar Fathy
• Format: Article
• Language: English
• ISSN: 1083-7450; 1097-9867; 1097-9867
• DOI: 10.1080/10837450.2024.2343320

In this study, a new gastro-floating sustained-release tablet (GFT) with a combination of Etoricoxib (ET) and Famotidine (FM) was successfully developed. GFTs were prepared by using a combination of hydrophilic swellable natural/semi-synthetic polymers as a controlled-release layer. Through a 2 full factorial statistical experimental design, the effects of formulation factors on the release of GFTs were conducted. The ideal floating tablet (FT) comprised konjac-gum (150 mg), guar-gum (26.57 mg), xanthan-gum (54.17 mg), and HPMC-K15-M (69.25 mg). The ideal FT exhibited a high swelling index (SI) (297.7%) and rapid FLT (around 50 sec) in 0.1 N HCl as well as controlled release of ET (22.43% in 1 h and 77.47% in 8 h) and FM (24.89% in 1 h and 93.82% in 8 h) with the absence of any drug-excipient interactions. The AUC (ng. h/mL) of ET and FM in the GFTs were approximately double-fold of the market, respectively. The relative bioavailability was (207.48 ± 12.02% and 208.51 ± 13.11%) compared with commercial tablets. The X-ray imaging showed a promising buoyancy ability for approximately 8 h. These findings revealed the successful preparation of the sustained-release floating tablet with improved dual drug delivery.